KRAS mutation: from undruggable to druggable in cancer
Abstract Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of...
Main Authors: | Lamei Huang, Zhixing Guo, Fang Wang, Liwu Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-11-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-021-00780-4 |
Similar Items
-
Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
by: Bin Lu, et al.
Published: (2021-10-01) -
Targeting the undruggable oncogenic KRAS: the dawn of hope
by: Hande Asimgil, et al.
Published: (2022-01-01) -
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
by: Kuen Kuen Lam, et al.
Published: (2023-02-01) -
Prediction of Druggable Allosteric Sites of Undruggable Multidrug Resistance Efflux Pump Proteins
by: Pradeep Kumar Yadalam, et al.
Published: (2023-09-01) -
KRAS: A Druggable Target in Colon Cancer Patients
by: Francesca Negri, et al.
Published: (2022-04-01)